hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-25. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
=== 2010–2012: Early growth === Blockchain analysts estimate that Nakamoto had mined about one million bitcoins before he disappeared in 2010 and handed the network alert key and control of the code repository over to Gavin Andresen. Andresen later became lead developer at the Bitcoin Foundation, an organization founded in September 2012 to promote bitcoin. After early "proof-of-concept" transactions, the first major users of bitcoin were black markets, such as the dark web Silk Road. During its 30 months of existence, beginning in February 2011, Silk Road exclusively accepted bitcoins as payment, transacting ₿9.9 million, worth about $214 million.
Timothy A. "Tim" Springer (born February 23, 1948) is an American biochemist, immunologist, and biophysicist known for his foundational work on cell adhesion, protein allostery, vascular biology, and immune regulation. He is the Latham Family Professor at Harvard Medical School in the Departments of Biological Chemistry and Molecular Pharmacology and of Pediatrics, and a faculty member in the Program in Cellular and Molecular Medicine and Division of Hematology at Boston Children's Hospital (BCH). Springer is best known for discovering the first cell adhesion molecules of the immune system, the first relationships among integrins—between LFA-1 and Mac-1—and the three-step model for leukocyte emigration from the vasculature. He is also known for entrepreneurship while continuing to run an NIH-funded laboratory, for founding the Institute for Protein Innovation, and for training students and postdoctoral fellows, two of whom are in the National Academy of Sciences. In recent years, his laboratory has focused on structural and mechanobiological studies of integrins, transforming growth factor β (TGF-β), and synthetic scaffolds to zonulate organoids for regenerative medicine..
Corin, also called atrial natriuretic peptide-converting enzyme, is a protein that in humans is encoded by the CORIN gene. Human corin, a polypeptide of 1042 amino acids, consists of an N-terminal cytoplasmic domain, a transmembrane domain and an extracellular region with two frizzled-like domains, eight LDL receptor-like domains, a scavenger receptor-like domain and a C-terminal trypsin-like serine protease domain. Corin is synthesized as a zymogen that is activated by PCSK6. Corin exhibits a trypsin-like catalytic activity favoring basic residues at the P1 position. Human corin contains 19 N-glycosylation sites. N-glycans promote corin expression on the cell surface and protect corin from metalloproteinase-mediated shedding.
=== Studies indicating negligible effects === Studies in 2005 and earlier have concluded that DU ammunition has no measurable detrimental health effects. A 1999 literature review conducted by the Rand Corporation stated: "No evidence is documented in the literature of cancer or any other negative health effect related to the radiation received from exposure to depleted or natural uranium, whether inhaled or ingested, even at very high doses," and a RAND report authored by the U.S. Defense department undersecretary charged with evaluating DU hazards considered the debate to be more political than scientific. A 2001 oncology study concluded that "the present scientific consensus is that DU exposure to humans, in locations where DU ammunition was deployed, is very unlikely to give rise to cancer induction". Former NATO Secretary General Lord Robertson stated in 2001 that "the existing medical consensus is clear. The hazard from depleted uranium is both very limited, and limited to very specific circumstances". A 2002 study from the Australian defense ministry concluded that "there has been no established increase in mortality or morbidity in workers exposed to uranium in uranium processing industries...
Sources: en.wikipedia.org
== History == Cambrex was founded in 1979, when the Ennis Family acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem was renamed Cambrex Corporation and became listed on NASDAQ. In 1990, Cambrex was listed on the NYSE. Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco. Through multiple acquisitions during the late 1990s, the firm entered the bioscience and the chiral enzymatic catalyst markets. Cambrex acquired two contract biopharmaceutical manufacturing facilities in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales. In 2007, the firm decided to focus on its core competencies and sold the biologics business to Lonza Group. In 2008, Prosyntest (now Cambrex Tallinn) was acquired, and Steve Klosk was appointed CEO, while remaining President. To broaden their biocatalysis platform, Cambrex acquired IEP in 2010, now known as Cambrex IEP. In 2019, Cambrex acquired Avista Pharma Solutions for $252m to become a fully integrated CDMO. In late 2019, Cambrex was acquired by an affiliate of the Permira funds. In 2020, Cambrex completed a major expansion at its Edinburgh, UK facility known for solid form screening alongside a biopharmaceutical expansion at its Durham, NC facility. Thomas Loewald was appointed CEO of Cambrex in September 2020. In 2022, Cambrex acquired Q1 Scientific, based out of Waterford, Ireland.
=== Rotator cuff disease === A 2022 review and meta-analysis showed improved patient-rated outcomes in patients with partial rotator cuff tears. At 8 weeks post injection, they found PRP to be effective. A 2021 prospective study examined the effectiveness of PRP for partial thickness rotator cuff tears. Patients were given 2 separate PRP injections and followed for 2 years. The study noted: "No adverse events were seen in any patient. Based on global rating scores positive results were seen in 77.9 % of patients at 6 months, 71.6 % at 1 year, and 68.8 % of patients at 2 years". They found PRP most effective in more damaged tendons. A 2021 meta-analysis found that PRP was effective for partial rotator cuff tears but the effects were no longer evident at 1 year. PRP has been shown to be superior to cortisone injections in several studies. This is especially evident in the longer term. A 2019 review found it not to be useful in rotator cuff disease. A 2018 review found that it may be useful. A 2009 review found few randomized controlled trials that adequately evaluated the safety and efficacy of PRP treatments and concluded that PRP was "a promising, but not proven, treatment option for joint, tendon, ligament, and muscle injuries".
Ribosomal DNA (rDNA) is more vulnerable to DNA damage than DNA elsewhere in the genome such that rDNA instability can lead to cellular senescence, and thus to SASP The high-mobility group proteins (HMGA) can induce senescence and SASP in a p53-dependent manner. Activation of the retrotransposon LINE1 can result in cytosolic DNA that activates the cGAS–STING cytosolic DNA sensing pathway upregulating SASP by induction of interferon type I. cGAS is essential for induction of cellular senescence by DNA damage. SASP secretion can also be initiated by the microRNAs miR-146 a/b. Senescent cells release mitochondrial double-stranded RNA (mt-dsRNA) into the cytosol driving the SASP via RIGI/MDA5/MAVS/MFN1. Moreover, senescent cells are hypersensitive to mt-dsRNA-driven inflammation due to reduced levels of PNPT1 and ADAR1.
== Function == This gene encodes one of the three alpha chains of type IX collagen, the major collagen component of hyaline cartilage. Type IX collagen, a heterotrimeric molecule, is usually found in tissues containing type II collagen, a fibrillar collagen. Mutations in this gene are associated with multiple epiphyseal dysplasia.
Today, it is widely planted in cities worldwide for its pollution tolerance and ornamental value. G. biloba wood is valued for its durability and used in crafts and sake-making, while its seeds are popular in Asian cuisine despite health risks, including potential carcinogenicity, allergic reactions, poisoning due to ginkgotoxin, drug interactions, and adverse effects such as bleeding and neurological symptoms, especially with excessive or improper use. Ginkgo-based products are widely marketed for cognitive benefits, although clinical research shows limited medical effectiveness except possibly for dementia, with approval in the European Union but not by the United States Food and Drug Administration.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.